Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma

A. Avigdor*, P. Raanani, I. Levi, I. Hardan, I. Ben-Bassat

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

60 Scopus citations

Abstract

We report two patients who were treated with thalidomide for resistant multiple myeloma (MM) and developed extramedullary plasmacytomas despite a good response in the bone marrow. The first patient had progressive disease 18 months post autologous peripheral stem cell transplant. Two and a half months after the initiation of thalidomide therapy extensive new plasmacytomas of the skin and nasal mucosa appeared while the medullary response continued. The second patient was treated with thalidomide for resistant MM. Despite a medullary response he developed neurological signs compatible with cranial nerve involvement and an MRI study was suggestive of a plasmacytoma involving the sellar region. We assume that a change in the expression of some adhesion molecules on the myeloma and/or the stromal cells is responsible for this phenomenon. Treating Physicians should be aware of this phenomenon in MM patients receiving thalidomide.

Original languageEnglish
Pages (from-to)683-687
Number of pages5
JournalLeukemia and Lymphoma
Volume42
Issue number4
DOIs
StatePublished - 2001
Externally publishedYes

Keywords

  • Adhesion molecules
  • Extramedullary plasmacytoma
  • Multiple myeloma
  • Resistant
  • Thalidomide

Fingerprint

Dive into the research topics of 'Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma'. Together they form a unique fingerprint.

Cite this